Evonik and Cassava Sciences enter supply agreement for Alzheimer’s drug candidate

pharmafile | March 10, 2021 | News story | Research and Development Alzheimer's, Cassava Sciences, Evonik 

Evonik has entered into an agreement to supply Cassava Sciences with large-scale, clinical-grade quantities of simufilam, a drug candidate for the treatment of Alzheimer’s disease.

Simufilam is a novel drug, discovered at Cassava Sciences, that targets both neuroinflammation and neurodegeneration.

In a double-blind, randomised, placebo-controlled Phase IIb study assessing the drug in Alzheimer’s, simufilam demonstrated robust effects on primary and secondary outcome measures, with no safety issues. Recently, Cassava announced that simufilam improved cognition in subjects with Alzheimer’s disease in a six-month interim analysis of an open-label study, with no safety issues.

The agreement with Cassava is the latest milestone in Evonik’s long heritage of contributions to the development and production of active pharmaceutical ingredients (APIs).

Evonik serves as a fully integrated contract development and manufacturing organisation with capabilities to manufacture customized APIs, select and supply functional excipients, develop parenteral or oral formulations, and manufacture finished drug products.

Cassava’s simufilam is produced at Evonik’s Tippecanoe site in the state of Indiana, USA.

Thomas Riermeier, Head of Evonik’s Health Care business line, said: “We are delighted to be collaborating with Cassava and contributing to fight Alzheimer’s together.

“We are committed to supporting Cassava in their goals to maintain the quality of life for millions of patients around the world and to further advance potential treatment options.”

Remi Barbier, President and CEO of Cassava Sciences, added: “I am pleased with our success to date in being an effective collaborator with Evonik, a company with a long, successful and reliable track record of supporting pharmaceutical supply chains.”

Darcy Jimenez

Related Content

Eli Lilly to seek FDA approval for experimental Alzheimer’s drug

Eli Lilly plans to seek accelerated FDA approval for its experimental Alzheimer’s drug donanemab, announcing …


Eli Lilly’s Alzheimer’s drug slows clinical decline in Phase II trial

Eli Lilly’s donanemab has shown significant slowing of decline in a composite measure of cognition …


Leukaemia drug nilotinib shows promise against Alzheimer’s in small clinical study

The leukemia drug nilotinib has shown promise in reducing the effects of Alzheimer’s disease and …

Latest content